Lilly's Zepbound Outperforms Wegovy in Weight Loss Trial
TL;DR Summary
Eli Lilly's Zepbound (tirzepatide) demonstrated superior weight loss results compared to Wegovy (semaglutide) in the SURMOUNT-5 clinical trial, with participants losing an average of 20.2% of their body weight versus 13.7% for Wegovy. The trial involved adults with obesity or overweight conditions without diabetes, and Zepbound, a dual GIP and GLP-1 receptor agonist, outperformed Wegovy on all primary and secondary endpoints. The safety profile was consistent with previous studies, with gastrointestinal issues being the most common side effects.
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Investors | Eli Lilly and Company
- Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study The Wall Street Journal
- Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says CNN
- Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial Bloomberg
- Zepbound results in more weight loss than Wegovy in trial, Eli Lilly says NBC News
Reading Insights
Total Reads
0
Unique Readers
13
Time Saved
16 min
vs 17 min read
Condensed
98%
3,361 → 78 words
Want the full story? Read the original article
Read on Investors | Eli Lilly and Company